Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that we have entered into an exclusive, worldwide licensing agreement with Harbour BioMed for the development and commercialization of HBM7020, a BCMAxCD3 bispecific T-cell engager under development by Harbour BioMed. The license covers all territories worldwide except for Greater China (Mainland China, Hong Kong, Taiwan and Macau)..

大冢制药株式会社（Otsuka）宣布，我们已与和铂医药达成一项独家的全球许可协议，用于开发和商业化HBM7020，一种由和铂医药研发的BCMAxCD3双特异性T细胞衔接器。该许可覆盖全球所有地区，但大中华区（中国大陆、香港、台湾和澳门）除外。

HBM7020 has been confirmed in preclinical studies to activate T cells, which are part of the immune system, and bring them into close proximity with antibody producing B cells and plasma cells to induce cell destruction. Since many autoimmune diseases involve B cells and plasma cells that produce autoantibodies, HBM7020 is expected to have broad efficacy against these diseases.

HBM7020 在临床前研究中已确认可激活免疫系统中的 T 细胞，并将它们与产生抗体的 B 细胞和浆细胞拉近，从而诱导细胞破坏。由于许多自身免疫疾病涉及产生自身抗体的 B 细胞和浆细胞，因此预期 HBM7020 对这些疾病具有广泛的疗效。

Otsuka Pharmaceutical plans to advance the development of HBM7020 as a therapeutic agent for autoimmune diseases..

大冢制药计划推进HBM7020作为自身免疫疾病治疗药物的开发。

Under the terms of the agreement, Otsuka will pay Harbour BioMed a total of U.S. $47 million in upfront and near-term milestones. Other payments are contingent on the achievement of specified development and commercial milestones. Otsuka will exclusively conduct development and commercialization worldwide, excluding Greater China, and will pay Harbour BioMed tiered royalties based on sales.

根据协议条款，大冢将向和铂医药支付总计4700万美元的预付款和近期里程碑款项。其他款项取决于达成特定的开发和商业里程碑。大冢将独家在全球（不包括大中华区）进行开发和商业化，并将基于销售额向和铂医药支付阶梯式特许权使用费。

Otsuka will fund all future development..

大冢将为所有未来的开发提供资金。

Makoto Inoue, president and representative director of Otsuka Pharmaceutical, noted, 'Otsuka is expanding our development pipeline in the autoimmune disease field by leveraging the antibody drug platform of our subsidiary Visterra, and the small molecule drug discovery platform of our subsidiary Jnana.

大冢制药的总裁兼代表董事井上真表示：“大冢正在通过其子公司Visterra的抗体药物平台和子公司Jnana的小分子药物发现平台，扩大我们在自身免疫疾病领域的发展管道。”

HBM7020 is expected to demonstrate efficacy in a broad range of autoimmune diseases in which B cells play a major role in disease pathogenesis, and we hope to contribute further to the field of specialized autoimmune diseases and thereby benefit patients.'.

HBM7020有望在B细胞在疾病发生中起主要作用的广泛自身免疫疾病中展现疗效，我们希望进一步为专业自身免疫疾病领域做出贡献，从而造福患者。

Dr. Jingsong Wang, founder, chairman, and CEO of Harbour BioMed commented, "We are delighted to collaborate with Otsuka, a global healthcare leader renowned for its innovative approach to addressing unmet medical needs. This collaboration underscores the strength of Harbour BioMed's proprietary Harbour Mice® and HBICE® technology platforms, which enable the rapid development of fully human bispecific antibodies with optimized safety and efficacy profiles. By leveraging our unique capabilities, we are well-positioned to advance next-generation biotherapeutics that can make a meaningful difference in patients' lives worldwide."

和铂医药创始人、董事长兼首席执行官王劲松博士表示：“我们非常高兴能与大冢合作。大冢是全球领先的医疗健康企业，以其创新方法解决尚未满足的医疗需求而闻名。此次合作彰显了和铂医药专有的Harbour Mice®和HBICE®技术平台的优势，这些平台能够快速开发安全性和疗效均得到优化的全人源双特异性抗体。凭借我们独特的技术实力，我们已做好准备，推进下一代生物治疗药物的研发，为全球患者的生活带来意义非凡的改变。”

About HBM7020

关于HBM7020

HBM7020 is a BCMAxCD3 bispecific antibody generated using Harbour BioMed's fully human HBICE

HBM7020是使用和铂医药全人源HBICE生成的BCMAxCD3双特异性抗体

bispecific technology and Harbour Mice

双特异性技术与 Harbour Mice

platform. It is designed to crosslink target cells and T cells by binding to BCMA and CD3 on the cell surface, leading to potent T cell activation and targeted cell elimination. By incorporating dual anti-BCMA binding sites for enhanced cell targeting and monovalent-optimized CD3 activity to minimize cytokine release syndrome (CRS), HBM7020 has demonstrated potent cytotoxicity with broad therapeutic potential in both immunological and oncological diseases.

平台。它通过结合细胞表面的BCMA和CD3，设计用于将目标细胞与T细胞交联，从而引发强烈的T细胞激活和靶向细胞清除。通过整合双重抗BCMA结合位点以增强细胞靶向性，并优化单价CD3活性以最小化细胞因子释放综合征（CRS），HBM7020在免疫疾病和肿瘤疾病中均显示出强大的细胞毒性和广泛的治疗潜力。

In August 2023, HBM7020 obtained IND clearance from the National Medical Products Administration (NMPA) to commence a Phase I trial for cancer in China..

2023年8月，HBM7020获得中国国家药品监督管理局（NMPA）的IND批准，可在中国启动针对癌症的I期临床试验。

About Otsuka

关于大冢制药

Otsuka Pharmaceutical Co., Ltd. is a total healthcare company that focuses on each individual's potential to enhance their well-being. Our medical-related business provides treatments and diagnostics for both physical and mental health. Our nutraceutical business supports daily health maintenance and improvement.

大冢制药株式会社是一家全方位的医疗保健公司，专注于每个人的潜力以提升其健康水平。我们的医药相关业务提供针对身体和心理健康的治疗与诊断。我们的营养保健品业务则支持日常健康维护与改善。

Otsuka's unique products and services are based on scientific evidence, under the guidance of our corporate philosophy: .

大冢的独特产品和服务基于科学证据，在我们企业理念的指导下：。

About Harbour BioMed

关于和铂医药

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions..

和铂医药（港交所代码：02142）是一家全球性生物制药公司，致力于发现和开发免疫学及肿瘤学领域的新型抗体疗法。公司通过内部研发能力、全球战略合作的共同发现与共同开发，以及选择性收购，构建了强大且差异化的研发管线。